Effects of a novel Nodal-targeting monoclonal antibody in melanoma

Luigi Strizzi, Annamaria Sandomenico, Naira V. Margaryan, Annalia Focà, Luca Sanguigno, Thomas M. Bodenstine, Grace S. Chandler, David W. Reed, Alina Gilgur, Elisabeth A. Seftor, Richard E.B. Seftor, Zhila Khalkhali-Ellis, Antonio Leonardi, Menotti Ruvo, Mary J.C. Hendrix*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Nodal is highly expressed in various human malignancies, thus supporting the rationale for exploring Nodal as a therapeutic target. Here, we describe the effects of a novel monoclonal antibody (mAb), 3D1, raised against human Nodal. In vitro treatment of C8161 human melanoma cells with 3D1 mAb shows reductions in anchorage-independent growth and vasculogenic network formation. 3D1 treated cells also show decreases of Nodal and downstream signaling molecules, P-Smad2 and P-ERK and of P-H3 and CyclinB1, with an increase in p27. Similar effects were previously reported in human breast cancer cells where Nodal expression was generally down-regulated; following 3D1 mAb treatment, both Nodal and P-H3 levels are reduced. Noteworthy is the reduced growth of human melanoma xenografts in Nude mice treated with 3D1 mAb, where immunostaining of representative tumor sections show diminished P-Smad2 expression. Similar effects both in vitro and in vivo were observed in 3D1 treated A375SM melanoma cells harboring the active BRAF(V600E) mutation compared to treatments with IgG control or a BRAF inhibitor, dabrafenib. Finally, we describe a 3D1-based ELISA for the detection of Nodal in serum samples from cancer patients. These data suggest the potential of 3D1 mAb for selecting and targeting Nodal expressing cancers.

Original languageEnglish (US)
Pages (from-to)34071-34086
Number of pages16
Issue number33
StatePublished - 2015


  • Antibody
  • Cancer
  • Nodal
  • Therapy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Effects of a novel Nodal-targeting monoclonal antibody in melanoma'. Together they form a unique fingerprint.

Cite this